Ranked #2,710 of 8,699 institutional investors
Merck & Co., Inc.
Rahway, NJ
$807M
US stock portfolio at live prices · today −$1.6M (−0.20%)
Market closed. Prices as of Nov 20, 8:41 AM ET
- Value at quarter end (Q3 2026)
- $820M
- Change from Q2 2026
- +$293.9M (+55.84%)
- Positions
- 13 · 0 new, 0 sold out
- Filed
- Nov 13, 2026
Holdings
Q3 2026 13F, live pricesMRNA 57.0%PSNL 25.6%KYMR 11.4%AKTS 1.94%ALEC 1.01%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| MRNA Moderna, Inc. | 2,308,190 | $460M | 57.0% | Unchanged |
| PSNL Personalis, Inc. | 14,044,943 | $207M | 25.6% | Unchanged |
| KYMR Kymera Therapeutics, Inc. | 772,165 | $92.2M | 11.4% | Unchanged |
| AKTS Aktis Oncology, Inc. | 952,844 | $15.6M | 1.94% | Unchanged |
| ALEC Alector, Inc. | 3,545,719 | $8.2M | 1.01% | Unchanged |
| TRDA Entrada Therapeutics, Inc. | 1,739,768 | $8.1M | 1.00% | Unchanged |
| EIKN Eikon Therapeutics, Inc. | 1,666,666 | $7.9M | 0.98% | Unchanged |
| VRDN Viridian Therapeutics, Inc. | 93,414 | $2.9M | 0.36% | Unchanged |
| EVAX Evaxion A/S | 1,214,126 | $2.5M | 0.31% | Unchanged |
| STRO Sutro Biopharma, Inc. | 272,351 | $2.4M | 0.29% | Unchanged |
| XLO Xilio Therapeutics, Inc. | 105,982 | $796K | <0.1% | Unchanged |
| HURA TuHURA Biosciences, Inc. | 19,445 | $26K | <0.1% | Unchanged |
| NEUP Neuphoria Therapeutics Inc. | 10,027 | $23K | <0.1% | Unchanged |